Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma
Background: Malignant pleural mesothelioma (MPM) is an aggressive neoplasm arising from mesothelial lining of pleura. CD26 molecules preferentially expressed on epithelioid type of MPM. This study investigates the molecular mechanisms of CD26 regulating MPM cells in vitro and in vivo . Methods: Bioc...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2014-04, Vol.110 (9), p.2232-2245 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2245 |
|---|---|
| container_issue | 9 |
| container_start_page | 2232 |
| container_title | British journal of cancer |
| container_volume | 110 |
| creator | Yamamoto, J Ohnuma, K Hatano, R Okamoto, T Komiya, E Yamazaki, H Iwata, S Dang, N H Aoe, K Kishimoto, T Yamada, T Morimoto, C |
| description | Background:
Malignant pleural mesothelioma (MPM) is an aggressive neoplasm arising from mesothelial lining of pleura. CD26 molecules preferentially expressed on epithelioid type of MPM. This study investigates the molecular mechanisms of CD26 regulating MPM cells
in vitro
and
in vivo
.
Methods:
Biochemical and cell biological approaches were used for identifying a novel molecular target of MPM. Its contribution to tumour expansion has been also assessed using animal models. The clinical samples of MPM were also assessed for its expression.
Results:
We identify that cytostatic effects in MPM are mediated by somatostatin (SST) receptor 4 (SSTR4), being inhibited by the interaction of CD26 molecules. We also indicates that SSTR4-mediated cytostatic effects are regulated by SHP-2 PTP, and that this inhibitory effect by SST agonist is enhanced
via
lipid raft clustering of associated molecules following crosslinking of anti-CD26 antibody. Finally, using an
in vivo
xenograft model, we demonstrate that the anti-tumour effect of anti-CD26 mAb is enhanced when combined with SSTR4 agonist treatment, and that SSTR4 is highly coexpressed with CD26 on epithelioid or biphasic types of MPM tissues obtained from patients’ surgical specimens.
Conclusions:
Combination therapy with humanised anti-CD26 mAb and SSTR4 agonist may therefore potentiate anti-tumour effect on MPM. |
| doi_str_mv | 10.1038/bjc.2014.151 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4007235</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3289175811</sourcerecordid><originalsourceid>FETCH-LOGICAL-c546t-818b18a413e49d92506376763b52c58758ffe5a87a242228fcea4c15fe4e6bd73</originalsourceid><addsrcrecordid>eNptkc1rGzEQxUVoSZykt56LoPTWdfW50l4CwW2aQiBQ0rPQyrPOuruSI2kD_u8jx26aQk9iNL9585iH0HtK5pRw_aVduzkjVMyppEdoRiVnFdVMvUEzQoiqSMPICTpNaV3Khmh1jE6YUIIrombo909YTYPNffA4dDiF0eaQcvnwOIKDTQ4Ri2qEZW8zLLHbHtoOQ9eBywm3W7z4ympcJkY79CtvfcabAaZoBzxCCvkehr4In6O3nR0SvDu8Z-jX1be7xXV1c_v9x-LypnJS1LnSVLdUW0E5iGbZMElqrmpV81YyJ7WSuiyWVivLBGNMdw6scFR2IKBul4qfoYu97mZqi3EHPhcrZhP70catCbY3_3Z8f29W4dGIci_GZRH4eBCI4WGClM06TNEXz6YcudEN18_U5z3lYkgpQveygRKzi8aUaMwumt1UwT-8dvUC_8miAJ8OgE3ODl203vXpL6clYbqpC1ftuVRafgXxlbv_LX4CYy-nKQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1519893835</pqid></control><display><type>article</type><title>Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma</title><source>MEDLINE</source><source>Nature</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Yamamoto, J ; Ohnuma, K ; Hatano, R ; Okamoto, T ; Komiya, E ; Yamazaki, H ; Iwata, S ; Dang, N H ; Aoe, K ; Kishimoto, T ; Yamada, T ; Morimoto, C</creator><creatorcontrib>Yamamoto, J ; Ohnuma, K ; Hatano, R ; Okamoto, T ; Komiya, E ; Yamazaki, H ; Iwata, S ; Dang, N H ; Aoe, K ; Kishimoto, T ; Yamada, T ; Morimoto, C</creatorcontrib><description>Background:
Malignant pleural mesothelioma (MPM) is an aggressive neoplasm arising from mesothelial lining of pleura. CD26 molecules preferentially expressed on epithelioid type of MPM. This study investigates the molecular mechanisms of CD26 regulating MPM cells
in vitro
and
in vivo
.
Methods:
Biochemical and cell biological approaches were used for identifying a novel molecular target of MPM. Its contribution to tumour expansion has been also assessed using animal models. The clinical samples of MPM were also assessed for its expression.
Results:
We identify that cytostatic effects in MPM are mediated by somatostatin (SST) receptor 4 (SSTR4), being inhibited by the interaction of CD26 molecules. We also indicates that SSTR4-mediated cytostatic effects are regulated by SHP-2 PTP, and that this inhibitory effect by SST agonist is enhanced
via
lipid raft clustering of associated molecules following crosslinking of anti-CD26 antibody. Finally, using an
in vivo
xenograft model, we demonstrate that the anti-tumour effect of anti-CD26 mAb is enhanced when combined with SSTR4 agonist treatment, and that SSTR4 is highly coexpressed with CD26 on epithelioid or biphasic types of MPM tissues obtained from patients’ surgical specimens.
Conclusions:
Combination therapy with humanised anti-CD26 mAb and SSTR4 agonist may therefore potentiate anti-tumour effect on MPM.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.2014.151</identifier><identifier>PMID: 24743707</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/699/67/1059 ; 692/699/67/1641 ; Animals ; Antibodies ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; Asbestos ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Cancer therapies ; Cell growth ; Cell Line, Tumor ; Cytostatic Agents - therapeutic use ; Dipeptidyl Peptidase 4 - metabolism ; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use ; Drug Resistance ; Epidemiology ; Gene Deletion ; Humans ; Lung Neoplasms - drug therapy ; Medical prognosis ; Medical research ; Medical sciences ; Mesothelioma ; Mesothelioma - drug therapy ; Mesothelioma, Malignant ; Mice ; Molecular Medicine ; Motility ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Oncology ; Pleural Neoplasms - drug therapy ; Pneumology ; Receptors, Somatostatin - agonists ; Receptors, Somatostatin - genetics ; Translational Therapeutics ; Tumors ; Tumors of the respiratory system and mediastinum ; Xenograft Model Antitumor Assays</subject><ispartof>British journal of cancer, 2014-04, Vol.110 (9), p.2232-2245</ispartof><rights>The Author(s) 2014</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Apr 29, 2014</rights><rights>Copyright © 2014 Cancer Research UK 2014 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c546t-818b18a413e49d92506376763b52c58758ffe5a87a242228fcea4c15fe4e6bd73</citedby><cites>FETCH-LOGICAL-c546t-818b18a413e49d92506376763b52c58758ffe5a87a242228fcea4c15fe4e6bd73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007235/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007235/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,887,27931,27932,53798,53800</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28502896$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24743707$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamamoto, J</creatorcontrib><creatorcontrib>Ohnuma, K</creatorcontrib><creatorcontrib>Hatano, R</creatorcontrib><creatorcontrib>Okamoto, T</creatorcontrib><creatorcontrib>Komiya, E</creatorcontrib><creatorcontrib>Yamazaki, H</creatorcontrib><creatorcontrib>Iwata, S</creatorcontrib><creatorcontrib>Dang, N H</creatorcontrib><creatorcontrib>Aoe, K</creatorcontrib><creatorcontrib>Kishimoto, T</creatorcontrib><creatorcontrib>Yamada, T</creatorcontrib><creatorcontrib>Morimoto, C</creatorcontrib><title>Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Background:
Malignant pleural mesothelioma (MPM) is an aggressive neoplasm arising from mesothelial lining of pleura. CD26 molecules preferentially expressed on epithelioid type of MPM. This study investigates the molecular mechanisms of CD26 regulating MPM cells
in vitro
and
in vivo
.
Methods:
Biochemical and cell biological approaches were used for identifying a novel molecular target of MPM. Its contribution to tumour expansion has been also assessed using animal models. The clinical samples of MPM were also assessed for its expression.
Results:
We identify that cytostatic effects in MPM are mediated by somatostatin (SST) receptor 4 (SSTR4), being inhibited by the interaction of CD26 molecules. We also indicates that SSTR4-mediated cytostatic effects are regulated by SHP-2 PTP, and that this inhibitory effect by SST agonist is enhanced
via
lipid raft clustering of associated molecules following crosslinking of anti-CD26 antibody. Finally, using an
in vivo
xenograft model, we demonstrate that the anti-tumour effect of anti-CD26 mAb is enhanced when combined with SSTR4 agonist treatment, and that SSTR4 is highly coexpressed with CD26 on epithelioid or biphasic types of MPM tissues obtained from patients’ surgical specimens.
Conclusions:
Combination therapy with humanised anti-CD26 mAb and SSTR4 agonist may therefore potentiate anti-tumour effect on MPM.</description><subject>692/699/67/1059</subject><subject>692/699/67/1641</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols</subject><subject>Asbestos</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Cell growth</subject><subject>Cell Line, Tumor</subject><subject>Cytostatic Agents - therapeutic use</subject><subject>Dipeptidyl Peptidase 4 - metabolism</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - therapeutic use</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Gene Deletion</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Mesothelioma</subject><subject>Mesothelioma - drug therapy</subject><subject>Mesothelioma, Malignant</subject><subject>Mice</subject><subject>Molecular Medicine</subject><subject>Motility</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Oncology</subject><subject>Pleural Neoplasms - drug therapy</subject><subject>Pneumology</subject><subject>Receptors, Somatostatin - agonists</subject><subject>Receptors, Somatostatin - genetics</subject><subject>Translational Therapeutics</subject><subject>Tumors</subject><subject>Tumors of the respiratory system and mediastinum</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptkc1rGzEQxUVoSZykt56LoPTWdfW50l4CwW2aQiBQ0rPQyrPOuruSI2kD_u8jx26aQk9iNL9585iH0HtK5pRw_aVduzkjVMyppEdoRiVnFdVMvUEzQoiqSMPICTpNaV3Khmh1jE6YUIIrombo909YTYPNffA4dDiF0eaQcvnwOIKDTQ4Ri2qEZW8zLLHbHtoOQ9eBywm3W7z4ympcJkY79CtvfcabAaZoBzxCCvkehr4In6O3nR0SvDu8Z-jX1be7xXV1c_v9x-LypnJS1LnSVLdUW0E5iGbZMElqrmpV81YyJ7WSuiyWVivLBGNMdw6scFR2IKBul4qfoYu97mZqi3EHPhcrZhP70catCbY3_3Z8f29W4dGIci_GZRH4eBCI4WGClM06TNEXz6YcudEN18_U5z3lYkgpQveygRKzi8aUaMwumt1UwT-8dvUC_8miAJ8OgE3ODl203vXpL6clYbqpC1ftuVRafgXxlbv_LX4CYy-nKQ</recordid><startdate>20140429</startdate><enddate>20140429</enddate><creator>Yamamoto, J</creator><creator>Ohnuma, K</creator><creator>Hatano, R</creator><creator>Okamoto, T</creator><creator>Komiya, E</creator><creator>Yamazaki, H</creator><creator>Iwata, S</creator><creator>Dang, N H</creator><creator>Aoe, K</creator><creator>Kishimoto, T</creator><creator>Yamada, T</creator><creator>Morimoto, C</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20140429</creationdate><title>Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma</title><author>Yamamoto, J ; Ohnuma, K ; Hatano, R ; Okamoto, T ; Komiya, E ; Yamazaki, H ; Iwata, S ; Dang, N H ; Aoe, K ; Kishimoto, T ; Yamada, T ; Morimoto, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c546t-818b18a413e49d92506376763b52c58758ffe5a87a242228fcea4c15fe4e6bd73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>692/699/67/1059</topic><topic>692/699/67/1641</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols</topic><topic>Asbestos</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Cell growth</topic><topic>Cell Line, Tumor</topic><topic>Cytostatic Agents - therapeutic use</topic><topic>Dipeptidyl Peptidase 4 - metabolism</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - therapeutic use</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Gene Deletion</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Mesothelioma</topic><topic>Mesothelioma - drug therapy</topic><topic>Mesothelioma, Malignant</topic><topic>Mice</topic><topic>Molecular Medicine</topic><topic>Motility</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Oncology</topic><topic>Pleural Neoplasms - drug therapy</topic><topic>Pneumology</topic><topic>Receptors, Somatostatin - agonists</topic><topic>Receptors, Somatostatin - genetics</topic><topic>Translational Therapeutics</topic><topic>Tumors</topic><topic>Tumors of the respiratory system and mediastinum</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamamoto, J</creatorcontrib><creatorcontrib>Ohnuma, K</creatorcontrib><creatorcontrib>Hatano, R</creatorcontrib><creatorcontrib>Okamoto, T</creatorcontrib><creatorcontrib>Komiya, E</creatorcontrib><creatorcontrib>Yamazaki, H</creatorcontrib><creatorcontrib>Iwata, S</creatorcontrib><creatorcontrib>Dang, N H</creatorcontrib><creatorcontrib>Aoe, K</creatorcontrib><creatorcontrib>Kishimoto, T</creatorcontrib><creatorcontrib>Yamada, T</creatorcontrib><creatorcontrib>Morimoto, C</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamamoto, J</au><au>Ohnuma, K</au><au>Hatano, R</au><au>Okamoto, T</au><au>Komiya, E</au><au>Yamazaki, H</au><au>Iwata, S</au><au>Dang, N H</au><au>Aoe, K</au><au>Kishimoto, T</au><au>Yamada, T</au><au>Morimoto, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2014-04-29</date><risdate>2014</risdate><volume>110</volume><issue>9</issue><spage>2232</spage><epage>2245</epage><pages>2232-2245</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Background:
Malignant pleural mesothelioma (MPM) is an aggressive neoplasm arising from mesothelial lining of pleura. CD26 molecules preferentially expressed on epithelioid type of MPM. This study investigates the molecular mechanisms of CD26 regulating MPM cells
in vitro
and
in vivo
.
Methods:
Biochemical and cell biological approaches were used for identifying a novel molecular target of MPM. Its contribution to tumour expansion has been also assessed using animal models. The clinical samples of MPM were also assessed for its expression.
Results:
We identify that cytostatic effects in MPM are mediated by somatostatin (SST) receptor 4 (SSTR4), being inhibited by the interaction of CD26 molecules. We also indicates that SSTR4-mediated cytostatic effects are regulated by SHP-2 PTP, and that this inhibitory effect by SST agonist is enhanced
via
lipid raft clustering of associated molecules following crosslinking of anti-CD26 antibody. Finally, using an
in vivo
xenograft model, we demonstrate that the anti-tumour effect of anti-CD26 mAb is enhanced when combined with SSTR4 agonist treatment, and that SSTR4 is highly coexpressed with CD26 on epithelioid or biphasic types of MPM tissues obtained from patients’ surgical specimens.
Conclusions:
Combination therapy with humanised anti-CD26 mAb and SSTR4 agonist may therefore potentiate anti-tumour effect on MPM.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>24743707</pmid><doi>10.1038/bjc.2014.151</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2014-04, Vol.110 (9), p.2232-2245 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4007235 |
| source | MEDLINE; Nature; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | 692/699/67/1059 692/699/67/1641 Animals Antibodies Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Combined Chemotherapy Protocols Asbestos Biological and medical sciences Biomedical and Life Sciences Biomedicine Cancer Research Cancer therapies Cell growth Cell Line, Tumor Cytostatic Agents - therapeutic use Dipeptidyl Peptidase 4 - metabolism Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Drug Resistance Epidemiology Gene Deletion Humans Lung Neoplasms - drug therapy Medical prognosis Medical research Medical sciences Mesothelioma Mesothelioma - drug therapy Mesothelioma, Malignant Mice Molecular Medicine Motility Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Oncology Pleural Neoplasms - drug therapy Pneumology Receptors, Somatostatin - agonists Receptors, Somatostatin - genetics Translational Therapeutics Tumors Tumors of the respiratory system and mediastinum Xenograft Model Antitumor Assays |
| title | Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T07%3A02%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Regulation%20of%20somatostatin%20receptor%204-mediated%20cytostatic%20effects%20by%20CD26%20in%20malignant%20pleural%20mesothelioma&rft.jtitle=British%20journal%20of%20cancer&rft.au=Yamamoto,%20J&rft.date=2014-04-29&rft.volume=110&rft.issue=9&rft.spage=2232&rft.epage=2245&rft.pages=2232-2245&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.2014.151&rft_dat=%3Cproquest_pubme%3E3289175811%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1519893835&rft_id=info:pmid/24743707&rfr_iscdi=true |